The HER2-specific tyrosine kinase inhibitor (TKI) tucatinib and the ADC T‐DXd have clinically relevant activity in pretreated HER2-positive breast cancer and both drugs were recently approved by EMA. Here, ERBB2 is linked to breast cancer.